Position statements

This position statement sets out our view on the use of AI methods in the generation and reporting of evidence considered by its evaluation programmes.

This document sets out our intention to develop our approach to: providing guidance for technology developers on best practice for artificial intelligence (AI)-based methods to support the evidence generation for their technologies evaluating AI-based technologies for use in the NHS exploring the use of AI-based tools in our own internal processes.

The UK Government is a signatory and party to the WHO Framework Convention on Tobacco Control (FCTC). As an Arm’s Length Body of Government, NICE has an obligation under Article 5.3 of the FCTC to protect public health policies from the commercial and other vested interests of the tobacco industry. This position statement sets out how NICE meets those obligations.

There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is appropriate. The procedure for each point is described in this position statement.

Our approach to biosimilar technologies.

NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines Optimisation and Chemotherapy Clinical Reference Groups (CRGs).

Our recommendations around the use of the EQ-5D-5L value set for England.

Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised regarding the applicability of NICE technology appraisals for patients who have previously received the same medication as part of a clinical trial.

This position statement sets out NICE's view on the use of disease-specific reference models and disease-specific reference case extensions in the economic evaluation of interventions considered by its evaluation programmes.